Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Laurus Labs Ltd. Share Price
Day's Range
Day's Range
Low
₹1,561.10
High
₹1,586.10
Price Summary
| Previous Close | ₹1,569.10 |
|---|---|
| Day's Range | ₹1,561.10 - ₹1,586.10 |
| Open | ₹1,577.70 |
| 52 Week Range | ₹810.05 - ₹1,600.10 |
| Volume | 8,32,643 |
| Market Cap | ₹0.09 |
| Previous Close | ₹1,569.70 |
|---|---|
| Day's Range | ₹1,563.00 - ₹1,583.85 |
| Open | ₹1,577.50 |
| 52 Week Range | ₹810.75 - ₹1,599.90 |
| Volume | 21,713 |
| Market Cap | ₹0.09 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 13,065.00 |
|---|---|
| Market Cap (₹ in Mn) | 0.09 |
| Dividend Yield(%) | 0.13 |
| Price/Earning (TTM) | 95.90 |
| TTM EPS (₹) | 16.45 |
| P/E Ratio | 60.25 |
| Book Value(₹) | 16.16 |
| PAT Margin (%) | 13.06 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 18.20 |
| Trade Value ( ₹ in Lacs) | 340.83 |
|---|---|
| Market Cap (₹ in Mn) | 0.09 |
| Dividend Yield(%) | 0.13 |
| Price/Earning (TTM) | 95.90 |
| TTM EPS (₹) | 16.45 |
| P/E Ratio | 60.25 |
| Book Value(₹) | 16.16 |
| PAT Margin (%) | 13.06 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 18.20 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 52169.8 | 16500.1 |
| Expenses | N/A | N/A |
| PBT | 5038.1 | 3302.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 3803.9 | 2519.0 |
About Laurus Labs Ltd.
| Founded | 2005 |
|---|---|
| NSE Symbol | LAURUSLABS |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,66,178.79 | 1,951.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,96,095.00 | 7,284.55 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,91,530.43 | 5,055.20 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,28,516.16 | 8,839.30 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,14,318.19 | 1,399.65 | 1,165.70 - 1,165.70 |
| Zydus Lifesciences Ltd. | 1,12,693.00 | 1,114.25 | 835.50 - 835.50 |
| Lupin Ltd. | 1,10,001.57 | 2,396.00 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,05,274.12 | 1,083.70 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,05,068.24 | 2,546.90 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 98,742.15 | 1,164.80 | 1,148.40 - 1,148.40 |
No Records Found
Latest News
Laurus Labs informs about AGM
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that it enclosed the Notice convening the 21st Annual General Meeting (‘AGM’) of shareholders of the Company, scheduled to be held on Thursday, July 2, 2026 at 3.00 pm (IST) through Video Conferencing (‘VC’)/ through Other Audio-Visual Means (‘OAVM’). The Notice of 21st AGM is also available on the Company’s website at www.lauruslabs.com.
The above information is a part of company’s filings submitted to BSE.
Laurus Labs informs about newspaper advertisements
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that it enclosed copies of the newspaper advertisements pertaining to Notice to Shareholders with respect to, ‘Submission of TDS related documents for 2nd Interim Dividend for FY 2025-26’. The advertisements were published in ‘Business Standard’ (English) and ‘Prajasakti’ (Telugu) on May 07, 2026.
Laurus Labs informs about press release
Cipla informs about financial results
Sanofi India informs about resignation of director
Pursuant to Regulation 30 of the Listing Regulations, Sanofi India has informed that Rachid Ayari (DIN:10408699) vide his letter dated 22nd July 2026, had conveyed his decision to step down from his current role as the Whole Time Director, Chief Financial Officer and Key Managerial Personnel of the Company with effect from the close of business hours on 30th September 2026, in view of his transition to another role within the Sanofi group. Accordingly, Rachid Ayari shall cease to be the Whole Time Director, Chief Financial Officer, Key Managerial Personnel and shall also cease to be Senior Management Personnel and member of the Risk Management Committee effective from the close of business hours on 30th September 2026. The Company places on record its sincere appreciation to Rachid Ayari for his valuable contributions, expert guidance, and dedicated assistance provided during his tenure with the Company. The Company is in the process of identifying a suitable candidate for the position of Chief Financial Officer, who will also be designated as a Key Managerial Personnel. The Company will inform the Stock Exchanges of the appointment in due course. The information required in terms of Regulation 30 read with Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 is enclosed as ‘Annexure-I’ and letter received from Rachid Ayari is enclosed as ‘Annexure – II’.
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Laurus Labs Ltd. is ₹1,569.10 as of 2026-07-23.
The market capitalisation of Laurus Labs Ltd. is ₹85,232.48 as of 2026-07-22.
The 1-year return of Laurus Labs Ltd. is 745.75% as of 2026-07-23.
The P/E ratio of Laurus Labs Ltd. is 60.25 as of 2026-07-23.
The 52-week high and low of Laurus Labs Ltd. are ₹1,600.10 and ₹810.05, respectively, as of 2026-07-23.
People Also Ask
Laurus Labs Ltd. provides active pharmaceutical ingredients, generic formulations and contract‑development/manufacturing services, with strengths in antivirals, oncology and chronic therapies.
Laurus Labs Ltd. collaborates via API and formulation supply agreements and CDMO partnerships with global generic and branded pharma companies that serve hospitals worldwide.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
